Literature DB >> 27471634

CD137 signaling in Hodgkin and Reed-Sternberg cell lines induces IL-13 secretion, immune deviation and enhanced growth.

Sakthi Rajendran1, Weng Tong Ho1, Herbert Schwarz2.   

Abstract

CD137 and its ligand, CD137L, are expressed on activated T cells and antigen-presenting cells (APC), respectively, and are powerful inducers of cellular, type 1 immune responses. CD137 is ectopically expressed by Hodgkin and Reed-Sternberg (HRS) cells, the malignant cells in Hodgkin lymphoma (HL). Here we report that CD137 transmits signals into HRS cells, which induce the secretion of IL-13. IL-13 in conditioned supernatants of HRS cell lines inhibits the secretion of IFNγ by peripheral blood mononuclear cells (PBMC). Since IFNγ is essential for the development of a type 1 immune response, CD137-induced IL-13 secretion facilitates escape from immune surveillance. Further, CD137-induced IL-13 enhances the growth of HRS cell lines. CD137, IL-13 double-positive cells could be detected in the majority (58%) of HL patient samples, providing clinical evidence for a role of IL-13 induction by CD137 during HL pathogenesis. This study validates CD137 as a candidate target for immunotherapy of HL.

Entities:  

Keywords:  CD137; Hodgkin Lymphoma; IL-13; immune deviation; immune escape; proliferation

Year:  2016        PMID: 27471634      PMCID: PMC4938358          DOI: 10.1080/2162402X.2016.1160188

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  29 in total

Review 1.  CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction.

Authors:  Zhe Shao; Herbert Schwarz
Journal:  J Leukoc Biol       Date:  2010-07-19       Impact factor: 4.962

2.  Levels of soluble CD137 are enhanced in sera of leukemia and lymphoma patients and are strongly associated with chronic lymphocytic leukemia.

Authors:  M Furtner; R H Straub; S Krüger; H Schwarz
Journal:  Leukemia       Date:  2005-05       Impact factor: 11.528

Review 3.  Interleukin 13: a growth factor in hodgkin lymphoma.

Authors:  B F Skinnider; U Kapp; T W Mak
Journal:  Int Arch Allergy Immunol       Date:  2001-12       Impact factor: 2.749

4.  CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling.

Authors:  J Langstein; J Michel; J Fritsche; M Kreutz; R Andreesen; H Schwarz
Journal:  J Immunol       Date:  1998-03-01       Impact factor: 5.422

Review 5.  Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance.

Authors:  Donatella Aldinucci; Marta Celegato; Naike Casagrande
Journal:  Cancer Lett       Date:  2015-10-23       Impact factor: 8.679

Review 6.  Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways.

Authors:  Shengdian Wang; Lieping Chen
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

7.  Trogocytic CD137 transfer causes an internalization of CD137 ligand on murine APCs leading to reduced T cell costimulation.

Authors:  Zhe Shao; Zulkarnain Harfuddin; Wan Lu Pang; Emily Nickles; Liang Kai Koh; Herbert Schwarz
Journal:  J Leukoc Biol       Date:  2015-03-12       Impact factor: 4.962

Review 8.  Immune regulation by 4-1BB and 4-1BBL: complexities and challenges.

Authors:  Chao Wang; Gloria H Y Lin; Ann J McPherson; Tania H Watts
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 9.  CD137, implications in immunity and potential for therapy.

Authors:  Elaine Thum; Zhe Shao; Herbert Schwarz
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

10.  Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells.

Authors:  U Kapp; W C Yeh; B Patterson; A J Elia; D Kägi; A Ho; A Hessel; M Tipsword; A Williams; C Mirtsos; A Itie; M Moyle; T W Mak
Journal:  J Exp Med       Date:  1999-06-21       Impact factor: 14.307

View more
  7 in total

Review 1.  Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors:  Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-30       Impact factor: 8.110

2.  Epstein-Barr virus-induced ectopic CD137 expression helps nasopharyngeal carcinoma to escape immune surveillance and enables targeting by chimeric antigen receptors.

Authors:  Mukul Prasad; Sashigala Ponnalagu; Qun Zeng; Khang Luu; Si Min Lang; Hiu Yi Wong; Man Si Cheng; Meihui Wu; Karthik Mallilankaraman; Radoslaw Mikolaj Sobota; Yan Ting Lim; Loo Chien Wang; Chuan Keng Goh; Kai Xun Joshua Tay; Kwok Seng Loh; Cheng-I Wang; Wen-Hsien Lee; Boon Cher Goh; Chwee Ming Lim; Herbert Schwarz
Journal:  Cancer Immunol Immunother       Date:  2022-03-17       Impact factor: 6.630

Review 3.  Current and Emerging Approaches to Study Microenvironmental Interactions and Drug Activity in Classical Hodgkin Lymphoma.

Authors:  Naike Casagrande; Cinzia Borghese; Donatella Aldinucci
Journal:  Cancers (Basel)       Date:  2022-05-14       Impact factor: 6.575

4.  Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells.

Authors:  Sakthi Rajendran; Yating Li; Evelyn Ngoh; Hiu Yi Wong; Man Si Cheng; Cheng-I Wang; Herbert Schwarz
Journal:  Front Oncol       Date:  2019-09-24       Impact factor: 6.244

5.  Destroy, what destroys you.

Authors:  Khang Luu; Emily Nickles; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2019-11-03       Impact factor: 8.110

Review 6.  The Hodgkin Lymphoma Immune Microenvironment: Turning Bad News into Good.

Authors:  Victoria Menéndez; José L Solórzano; Sara Fernández; Carlos Montalbán; Juan F García
Journal:  Cancers (Basel)       Date:  2022-03-07       Impact factor: 6.639

Review 7.  The role of trogocytosis in immune surveillance of Hodgkin lymphoma.

Authors:  Qun Zeng; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2020-06-17       Impact factor: 8.110

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.